We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Tacrolimus as Secondary Intervention vs. Continuation of Cyclosporine in Renal Transplant Patients With Chronic Renal Allograft Failure (CRAF)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: March 17, 2008
Last Update Posted: February 16, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Astellas Pharma Canada, Inc.
Information provided by (Responsible Party):
Astellas Pharma Inc
March 10, 2008
March 17, 2008
February 16, 2017
April 1999
February 2006   (Final data collection date for primary outcome measure)
Graft Survival [ Time Frame: 5 years ]
Same as current
Complete list of historical versions of study NCT00637143 on ClinicalTrials.gov Archive Site
Patient Survival [ Time Frame: 5 years ]
Same as current
Not Provided
Not Provided
Tacrolimus as Secondary Intervention vs. Continuation of Cyclosporine in Renal Transplant Patients With Chronic Renal Allograft Failure (CRAF)
Prograf® (Tacrolimus) as Secondary Intervention vs. Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure
The purpose of this study is to compare renal transplant recipients on cyclosporine maintenance therapy vs. those converted to tacrolimus-based immunosuppression with respect to renal outcomes.
The objective of this study is to compare the incidence, progression and severity of chronic renal allograft failure in at-risk patients who are converted from cyclosporine to tacrolimus-based immunosuppression to patients who remain on cyclosporine.
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Renal Transplantation
  • Chronic Renal Allograft Failure
  • Drug: Tacrolimus
    Other Names:
    • FK506
    • Prograf
  • Drug: Cyclosporine
    Other Name: Neoral
  • Experimental: 1
    Intervention: Drug: Tacrolimus
  • Active Comparator: 2
    Intervention: Drug: Cyclosporine
Jevnikar A, Arlen D, Barrett B, Boucher A, Cardella C, Cockfield SM, Rush D, Paraskevas S, Shapiro J, Shoker A, Yilmaz S, Zaltzman JS, Kiberd B. Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure. Transplantation. 2008 Oct 15;86(7):953-60. doi: 10.1097/TP.0b013e318186dd0c.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
February 2006
February 2006   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient is at least 3 months post-transplant of a cadaveric or living donor kidney
  • Patient has been on a cyclosporine-based immunosuppression regimen since the transplant
  • Patient has one of the following risk factors for chronic renal allograft failure at the baseline biopsy:

    • Serum creatinine: Male: >=2.0mg/dL (176.8 umol/L); Female: >= 1.7mg/dL (150.28 umol/L) 3 months or later post-transplant
    • Serum creatinine > 30% increased over post-discharge nadir
  • Patient has had a renal biopsy > 3 months after transplant and within 6 months prior to enrollment
  • Patient or legal guardian has signed and dated an IRB approved informed consent document
  • Female patient has a negative pregnancy test and agrees to practice effective birth control while receiving mycophenolate mofetil (MMF)

Exclusion Criteria:

  • Patient is dialysis dependent and has recurrence of primary or de novo renal disease
  • Patient has an estimated creatinine clearance <25mL/min
  • Patient has changed maintenance immunosuppressant therapy (e.g., azathioprine to MMF) within 3 months of randomization
  • Baseline biopsy shows acute rejection Grade >=IIB using Banff 95 criteria or >= Grade IIA using Banff 97 criteria
  • Patient requires antilymphocyte therapy to treat rejection at baseline or post-baseline biopsy
  • Patient has received an investigational immunosuppressant within 3 months, or has a known hypersensitivity to tacrolimus, or any excipients of the drug
  • Patient is a known carrier of any of the HIV viruses
Sexes Eligible for Study: All
12 Years and older   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Astellas Pharma Inc
Astellas Pharma Inc
Astellas Pharma Canada, Inc.
Study Chair: Central Contact Astellas Pharma Canada, Inc.
Astellas Pharma Inc
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP